The promising, but modest, clinical results of many human cancer vaccines indicate a need for vaccine adjuvants that can increase both the quantity and the quality of vaccine-induced, tumor-specific T cells. In this study we tested the immunological and antitumor effects of the proinflammatory cytokine, IL-23, in gp100 peptide vaccine therapy of established murine melanoma. Neither systemic nor...

BACKGROUND Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves as a potential potent trigger for the initiation of naturally occurring tumor immunity. The purpose of this study was to assess the feasibility, safety, and immunogenicity of an apoptotic tumor-autologous dendritic cell (DC) vaccine. METHODS AND FINDINGS We have modeled PND ...

Background: As an attempt to develop a strategy to improve the protective immune response to GM-CSF-secreting CT26 (GM-CSF/CT26) tumor vaccine, we have investigated whether the apoptogenic treatment of GM-CSF/CT26 prior to vaccination enhances the induction of anti-tumor immune response in mouse model. Methods: A carcinogeninduced mouse colorectal tumor, CT26 was transfected with GM-CSF gene us...

objective(s):tumor-associated antigen (taa) subunit-based vaccines constitute promising tools for anticancer immunotherapy. however, a major limitation in the development of such vaccines is the poor immunogenicity of peptides when used alone.the aim of this study was to develop an efficient vaccine delivery system and adjuvant to enhance anti-tumor activity of a synthetic her2/neu derived pept...

BACKGROUND We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune response to MUC1 tumor antigen, we have tested the efficacy of tumor irradiation combined with an MVA-MUC1-IL2 cancer vaccine (Transgene TG4010) for murine renal adenocarcinoma (Ren...

Antigenic differences between normal and malignant cells of the cancer patient form the rationale for clinical immunotherapeutic strategies. Because the antigenic phenotype of neoplastic cells varies widely among different cells within the same malignant cell-population, immunization with a vaccine that stimulates immunity to the broad array of tumor antigens expressed by the cancer cells is li...

Vaccination with tumor antigens causes tumor regression in some melanoma patients despite negligible expansion of vaccine-specific T cells. Vaccination may instead result in the expansion of T cells specific for tumor antigens not contained in the vaccine, thus facilitating tumor regression, according to two articles from Pierre Coulie and colleagues on pages 241 and 249. Tumor-specific T cells...

background: cervical cancer is the most prevalent tumor in developing countries and the second most frequent cancer among female population worldwide. specific human papillomaviruses and, most notably, hpv types 16 and 18 are recognized as being caus-ally associated with cervical carcinomas. the early hpv type 16 genes, e6 and e7, di-rectly participate in the in vitro transformation of primary ...

Background: Cervical cancer is the most prevalent tumor in developing countries and the second most frequent cancer among female population worldwide. Specific human papillomaviruses and, most notably, HPV types 16 and 18 are recognized as being caus-ally associated with cervical carcinomas. The early HPV type 16 genes, E6 and E7, di-rectly participate in the in vitro transformation of primary ...